Login to Your Account

Clinic Roundup

Monday, February 7, 2011
pSivida Corp., of Watertown, Mass., and Alimera Sciences Inc., of Atlanta, reported 36-month, top-line results for the FAME study of Iluvien in diabetic macular edema, showing statistically significant therapeutic effects with 28.9 percent at month 30 (p = 0.011) and 28.4 percent at month 33 (p = 0.042) of Iluvien patients gaining 15 or more letters compared to the control group, in which fewer than 17 percent of patients gained 15 or more letters.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription